MedPath

BRIACELL THERAPEUTICS CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 3
1 (25.0%)

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Phase 1
Recruiting
Conditions
Breast Cancer
Cancer of Breast
Cancer of the Breast
Tumors, Breast
Breast Tumor
Malignant Tumor of Breast
First Posted Date
2024-06-24
Last Posted Date
2024-08-26
Lead Sponsor
BriaCell Therapeutics Corporation
Target Recruit Count
18
Registration Number
NCT06471673
Locations
🇺🇸

Sarcoma Oncology Center, Santa Monica, California, United States

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Phase 3
Recruiting
Conditions
Metastatic Breast Cancer
Breast Neoplasm
End Stage Cancer
Breast Cancer
Breast Cancer Metastatic
Interventions
Drug: Treatment of Physician's Choice
Drug: Interferon infiltration of the inoculation site
First Posted Date
2023-10-10
Last Posted Date
2025-07-17
Lead Sponsor
BriaCell Therapeutics Corporation
Target Recruit Count
404
Registration Number
NCT06072612
Locations
🇺🇸

Hunterdon Medical Center, Flemington, New Jersey, United States

🇺🇸

University of Arizona-Cancer Center, Tucson, Arizona, United States

🇺🇸

Los Angeles cancer Network_Anaheim, Anaheim, California, United States

and more 57 locations

Combination Study of SV-BR-1-GM With Retifanlimab

Phase 1
Conditions
Breast Cancer
Breast Cancer Metastatic
Breast Neoplasm
Metastatic Breast Cancer
Interventions
First Posted Date
2017-11-01
Last Posted Date
2025-02-04
Lead Sponsor
BriaCell Therapeutics Corporation
Target Recruit Count
36
Registration Number
NCT03328026
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

🇺🇸

St. Joseph Heritage Healthcare, Santa Rosa, California, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

and more 11 locations

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Phase 1
Completed
Conditions
Breastcancer
Breast Neoplasm
Interventions
Biological: SV-BR-1-GM
Biological: Interferon-alpha-2b
First Posted Date
2017-03-01
Last Posted Date
2021-01-29
Lead Sponsor
BriaCell Therapeutics Corporation
Target Recruit Count
24
Registration Number
NCT03066947
Locations
🇺🇸

St. Joseph Heritage Healthcare, Santa Rosa, California, United States

🇺🇸

University of Miami/Sylvester at Plantation, Plantation, Florida, United States

🇺🇸

Cancer Center of Kansas (CCK), Wichita, Kansas, United States

and more 2 locations

News

Blood Test Monitoring PD-L1 Expression Shows Promise for Improving Immunotherapy Outcomes in Metastatic Breast Cancer

Clinical trials demonstrate that the LifeTracDx® blood test can monitor PD-L1 upregulation in metastatic breast cancer patients, with 76% showing increased expression after leronlimab treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.